Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-007: Intismeran Autogene + Pembrolizumab in Resectable LA cSCC
NCT06295809Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 20
01
Overview
A Phase 3 trial of intismeran autogene in cutaneous squamous cell carcinoma (cSCC), sponsored by Merck & Co.. Started Apr 2024; status: terminated.
02
Drugs
intismeran autogene
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06295809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295809.